Study summary · research use only
An evaluation of bremelanotide injection for the treatment of hypoactive sexual desire disorder
Plain-language summary
Paraphrased from the published abstract below — not a verdict on whether anything works.
This review summarizes bremelanotide's (Vyleesi) proposed mechanism of action, pharmacokinetics, and clinical trial data on its effects and adverse reactions in premenopausal women with hypoactive sexual desire disorder (HSDD), based on a PubMed literature search. Bremelanotide is a melanocortin receptor agonist hypothesized to trigger excitatory brain pathways involved in central melanocortin signaling. The review reports the most common adverse reaction was nausea (40%), and that while clinical trial data showed a significant change in validated questionnaires, the authors describe the overall clinical benefit as modest. It notes these findings should be interpreted alongside challenges in conducting well-designed female sexual dysfunction trials, including substantial placebo effects and outcome measures susceptible to expectation bias from long recall periods.
Abstract
Female sexual response implies a deep intertwining between psychosocial and neurobiological mediators. Regulation of central melanocortin signaling may enhance sexual desire. In premenopausal women with hypoactive sexual desire disorder (HSDD), melanocortin receptor agonist bremelanotide (Vyleesi) has been hypothesized to trigger excitatory brain pathways. Hereby we summarize bremelanotide's proposed mechanism of action, pharmacokinetics, efficacy and safety data derived from clinical trials. A literature search of peer-reviewed publications on the current evidence on the pharmacotherapy with bremelanotide was performed using the PubMed database. Bremelanotide appears to be moderately safe and well-tolerated; the most common adverse reaction is nausea (40%). Although data from clinical trials demonstrated a significant change in validated questionnaires, the overall clinical benefit appears to be modest. However, these results should be interpreted in the light of the dramatic challenges in conducting well-designed clinical trials for female sexual dysfunction, due to the significant placebo effect of pharmacotherapy, and the frequent use of outcome measures that are likely to be highly susceptible to expectation biases, such as long periods of recall of sexual and emotional response.
pepmg summarizes the peer-reviewed literature and links to every source — it sells nothing, ships nothing, and gives no medical, dosing, or human-use guidance. Don't just trust this summary: follow the citation to its source and read it yourself. Research use only.